Virtual Library

Start Your Search

Zhangzhou Huang



Author of

  • +

    Lunch & Poster Display session (ID 58)

    • Event: ELCC 2019
    • Type: Poster Display session
    • Track:
    • Presentations: 2
    • Moderators:
    • Coordinates: 4/11/2019, 12:30 - 13:00, Hall 1
    • +

      10P - The prevalence and prognostic significance of JAK2 mutation subtypes in non-small cell lung cancer from Chinese populations (ID 156)

      12:30 - 13:00  |  Author(s): Zhangzhou Huang

      • Abstract
      • Slides

      Background

      Although roles of JAK2 mutations in myeloproliferative neoplasms (MPN) are well established, roles of JAK2 mutations in the pathogenesis of non-small cell lung cancer (NSCLC) remain unclear. The aim of this study is to investigate mutations and prognosis of NSCLC harboring JAK2 mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A total of 766 patients with non-small-cell lung cancer were recruited between July 2012 and December 2016. The status of JAK2 mutations and other genes were detected by next generation sequencing.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      JAK2 gene mutation rate was 2.35% (18/766) in non-small cell lung cancer, including V617F (3 patients), L43I (2 patients), D768H (1 patient), G1066A (1 patient), W1020C (1 patient), S465R (1 patient), Q21E (1 patient), T842A (1 patient), C452* (1 patient), I404M (1 patient), P708Q (1 patient), S488* (1 patient), S1035L (1 patient), V387L(1 patient) and E575* (1 patient), and median overall survival (OS) for these patients was 19.0 months. Among them, all patients were JAK2 gene with co-occurring mutations. Briefly, patients with (n = 4) or without (n = 14) co-occurring EGFR mutations had a median OS of 23.0 months and 13.0 months respectively (P = 0.05); patients with (n = 11) or without (n = 7) co-occurring TP53 mutations had a median OS of 20.0 months and 7.0 months respectively (P = 0.01); patients with (n = 3) or without (n = 15) co-occurring ARID1A mutations had a median OS of 20.0 months and 13.0 months respectively (P = 0.32); patients with (n = 6) or without (n = 12) co-occurring KRAS mutations had a median OS of 11.5 months and 20.0 months respectively (P = 0.25).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      TP53 accompanied mutations might play a good prognosis in JAK2 gene mutation NSCLC. Next generation sequencing provides a simplified strategy and reasonably high detection rate for JAK2 mutation, which suggested application of the strategies into clinical molecular diagnostics.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.

    • +

      12P - Clinicopathologic characteristics of patients with TP63 mutations in Chinese non-small cell lung cancer (ID 158)

      12:30 - 13:00  |  Author(s): Zhangzhou Huang

      • Abstract
      • Slides

      Background

      Variation at TP63 has recently been shown to be associated with non-small cell lung cancer patients (NSCLC) in the Chinese population. There is some clinical evidence for the use of TP63 mutations as prognostic and predictive biomarker. The aim of this study is to investigate mutations and prognosis of NSCLC harboring TP63 mutations.

      a9ded1e5ce5d75814730bb4caaf49419 Methods

      A total of 1236 patients with non-small-cell lung cancer were recruited between July 2012 and December 2016. The status of TP63 mutations and other genes were detected by next generation sequencing.

      20c51b5f4e9aeb5334c90ff072e6f928 Results

      TP63 gene mutation rate was 2.02% (25/1236) in non-small cell lung cancer, including R643* (1 patient), H247N (1 patient), A139V (1 patient), V626F (1 patient), Q70* (1 patient), Q274E (1 patient), H615D (1 patient), R350T (1 patient), Y202Kfs*29 (1 patient), P229H (1 patient), M40V (1 patient), E409Q (1 patient), V179M (1 patient), W658* (1 patient), S365* (1 patient), T193M (1 patient), L50F (1 patient), A554E (1 patient), R226H (1 patient), Q99* (1 patient), S310N (1 patient), T169N (1 patient), R266Q (1 patient), D372H (1 patient), and P492T (1 patient), and median overall survival (OS) for these patients was 15.0 months. Among them, all patients were TP63 gene with co-occurring mutations. Briefly, patients with (n = 5) or without (n = 20) co-occurring EGFR mutations had a median OS of 22.5 months and 14.0 months respectively (P = 0.23); patients with (n = 21) or without (n = 4) co-occurring TP53 mutations had a median OS of 15.0 months and 13.0 months respectively (P = 0.33); patients with (n = 5) or without (n = 20) co-occurring BRAF mutations had a median OS of 14.0 months and 15.0 months respectively (P = 0.72); patients with (n = 5) or without (n = 20) co-occurring KRAS mutations had a median OS of 6.0 months and not up to now respectively (P < 0.01).

      fd69c5cf902969e6fb71d043085ddee6 Conclusions

      TP63 is structurally and functionally similar to TP53 and their activity as transcription factors is regulated by a wide repertoire of shared and unique post-translational modifications and interactions with regulatory cofactors. EGFR, TP53 and BRAF gene accompanied may have less correlation with TP63 mutation in NSCLC patients. KRAS accompanied mutations might play a worse prognosis in TP63 gene mutation NSCLC.

      b651e8a99c4375feb982b7c2cad376e9 Legal entity responsible for the study

      The authors.

      213f68309caaa4ccc14d5f99789640ad Funding

      Has not received any funding.

      682889d0a1d3b50267a69346a750433d Disclosure

      All authors have declared no conflicts of interest.

      cffcb1a185b2d7d5c44e9dc785b6bb25

      Only Active Members that have purchased this event or have registered via an access code will be able to view this content. To view this presentation, please login or select "Add to Cart" and proceed to checkout.